Cargando…
Targeting NEDDylation is a Novel Strategy to Attenuate Cisplatin-induced Nephrotoxicity
Although cisplatin remains a backbone of standard-of-care chemotherapy regimens for a variety of malignancies, its use is often associated with severe dose-limiting toxicities (DLT). Notably, 30%–40% of patients treated with cisplatin-based regimens are forced to discontinue treatment after experien...
Autores principales: | Jones, Trace M., Espitia, Claudia M., Chipollini, Juan, Lee, Benjamin R., Wertheim, Jason A., Carew, Jennifer S., Nawrocki, Steffan T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9973416/ https://www.ncbi.nlm.nih.gov/pubmed/36860653 http://dx.doi.org/10.1158/2767-9764.CRC-22-0340 |
Ejemplares similares
-
Targeting NEDDylation as a Novel Approach to Improve the Treatment of Head and Neck Cancer
por: Jones, Trace M., et al.
Publicado: (2021) -
Targeted CUL4A inhibition synergizes with cisplatin to yield long-term survival in models of head and neck squamous cell carcinoma through a DDB2-mediated mechanism
por: Jones, Trace M., et al.
Publicado: (2022) -
Moving beyond hydroxychloroquine: the novel lysosomal autophagy inhibitor ROC-325 shows significant potential in preclinical studies
por: Jones, Trace M., et al.
Publicado: (2019) -
Therapeutic Targeting of Autophagy for Renal Cell Carcinoma Therapy
por: Jones, Trace M., et al.
Publicado: (2020) -
Targeting JAK/STAT Signaling Antagonizes Resistance to Oncolytic Reovirus Therapy Driven by Prior Infection with HTLV-1 in Models of T-Cell Lymphoma
por: Islam, Shariful, et al.
Publicado: (2021)